title: Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
abstract: Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are widely recognized subtypes of C3 glomerulopathy. These ultra-rare renal diseases are characterized by fluid-phase dysregulation of the alternative complement pathway that leads to deposition of complement proteins in the renal glomerulus. Disease triggers are unknown and because targeted treatments are lacking, progress to end stage renal failure is a common final outcome. We studied soluble CR1, a potent regulator of complement activity, to test whether it restores complement regulation in C3 glomerulopathy. In vitro studies using sera from patients with DDD showed that soluble CR1 prevents dysregulation of the alternative pathway C3 convertase, even in the presence of C3 nephritic factors. In mice deficient in complement factor H and transgenic for human CR1, soluble CR1 therapy stopped alternative pathway activation, resulting in normalization of serum C3 levels and clearance of iC3b from glomerular basement membranes. Short-term use of soluble CR1 in a pediatric patient with end stage renal failure demonstrated its safety and ability to normalize activity of the terminal complement pathway. Overall, these data indicate that soluble CR1 re-establishes regulation of the alternative complement pathway and provide support for a limited trial to evaluate soluble CR1 as a treatment for DDD and C3GN.
authors.affiliation: Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, Iowa;
authors.forename: Yuzhou
authors.initials: Y
authors.lastname: Zhang
authors.forename: Carla M
authors.initials: CM
authors.lastname: Nester
authors.forename: Danniele G
authors.initials: DG
authors.lastname: Holanda
authors.forename: Henry C
authors.initials: HC
authors.lastname: Marsh
authors.forename: Russell A
authors.initials: RA
authors.lastname: Hammond
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Thomas
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Meyer
authors.forename: Lawrence G
authors.initials: LG
authors.lastname: Hunsicker
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Sethi
authors.forename: Richard J H
authors.initials: RJ
authors.lastname: Smith
mesh_terms: D000818:Animals; D002648:Child; D003176:Complement C3 / Q000032:analysis*; D017242:Complement Factor H / Q000502:physiology; D003170:Complement Pathway, Alternative; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D051379:Mice; D017463:Receptors, Complement 3b / Q000627:therapeutic use*
chemical_list: D003176:Complement C3; D017463:Receptors, Complement 3b; D017242:Complement Factor H
references.citation: J Exp Med. 1987 Apr 1;165(4):1095-112
references.pmid: 2951479
references.citation: J Clin Invest. 2008 Feb;118(2):608-18
references.pmid: 18202746
references.citation: Kidney Int. 2009 May;75(9):952-60
references.pmid: 19177158
references.citation: J Immunol Methods. 2008 Jun 1;335(1-2):1-7
references.pmid: 18410942
references.citation: J Am Soc Nephrol. 2007 Sep;18(9):2447-56
references.pmid: 17675665
references.citation: Kidney Int. 2012 Mar;81(5):434-41
references.pmid: 22157657
references.citation: Clin Exp Immunol. 1998 Apr;112(1):27-33
references.pmid: 9566786
references.citation: J Immunol. 1998 Jun 1;160(11):5273-9
references.pmid: 9605124
references.citation: J Immunol. 2010 Sep 15;185(6):3759-67
references.pmid: 20702729
references.citation: Curr Opin Nephrol Hypertens. 2013 Mar;22(2):231-7
references.pmid: 23318699
references.citation: Adv Nephrol Necker Hosp. 1989;18:249-69
references.pmid: 2522267
references.citation: Science. 1990 Jul 13;249(4965):146-51
references.pmid: 2371562
references.citation: Circulation. 2004 Sep 14;110(11 Suppl 1):II274-9
references.pmid: 15364875
references.citation: Pediatr Nephrol. 2012 May;27(5):773-81
references.pmid: 22105967
references.citation: Mol Immunol. 2011 Aug;48(14):1604-10
references.pmid: 21601923
references.citation: Nat Struct Mol Biol. 2011 Apr;18(4):463-70
references.pmid: 21317894
references.citation: J Am Soc Nephrol. 2005 Jul;16(7):2225-33
references.pmid: 15888559
references.citation: Clin J Am Soc Nephrol. 2012 Feb;7(2):265-74
references.pmid: 22223606
references.citation: Am Heart J. 2004 Jan;147(1):173-80
references.pmid: 14691437
references.citation: J Exp Med. 1991 May 1;173(5):1159-63
references.pmid: 1708809
references.citation: Nephrol Nurs J. 2007 May-Jun;34(3):295-302; quiz 303
references.pmid: 17644874
references.citation: Complement Inflamm. 1991;8(5-6):303-9
references.pmid: 1839374
references.citation: J Clin Invest. 2010 Oct;120(10):3702-12
references.pmid: 20852386
references.citation: Nat Genet. 2002 Aug;31(4):424-8
references.pmid: 12091909
references.citation: Circulation. 2007 Sep 11;116(11 Suppl):I83-8
references.pmid: 17846331
references.citation: Kidney Int. 2012 Aug;82(4):465-73
references.pmid: 22673887
references.citation: Kidney Int. 2010 Aug;78(3):279-86
references.pmid: 20445496
references.citation: Immunodefic Rev. 1990;2(1):17-41
references.pmid: 2164822
references.citation: J Exp Med. 1984 Jun 1;159(6):1669-85
references.pmid: 6233387
references.citation: J Biochem. 1992 May;111(5):573-8
references.pmid: 1386357
references.citation: Expert Rev Cardiovasc Ther. 2006 Sep;4(5):649-54
references.pmid: 17081086
references.citation: Mol Immunol. 2009 Jun;46(10):1942-50
references.pmid: 19411110